[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Therapy Class Overview: Rituximab biosimilar

October 2013 | 45 pages | ID: TC2666DD5E4EN
MP Advisors

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year. This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales of ~$21b in 2012.Commercial success of biosimilars will be depend both on affordability and accessibility assuming that the “copy molecule” is at par on efficacy, safety and similarity with the branded product. Uptake and marketing strategy of Remicade biosimilar will be closely watched by investors as well as companies developing/marketing Biosimilars. In this report, we have analyzed the market opportunity of rituximab biosimilar.What one would get if buy this report :

Challenges in developing rituximab Biosimilar- Worlwide and the emerging market experience in India and Mexico.

Rituximab biosililar pipeline, and the current status of clinical development
What are the Innovator's strategy in protecting rituximab franchise?
Competition to biosimilar rituximab from other innovative drugs.
Biosimilar guidelines in US, EU and other countries


More Publications